Backhaus, Sören Jan

[["dc.bibliographiccitation.artnumber","965512"],["dc.bibliographiccitation.journal","Frontiers in Cardiovascular Medicine"],["dc.bibliographiccitation.volume","9"],["dc.contributor.author","Evertz, Ruben"],["dc.contributor.author","Schulz, Alexander"],["dc.contributor.author","Lange, Torben"],["dc.contributor.author","Backhaus, Sören J."],["dc.contributor.author","Vollmann, Dirk"],["dc.contributor.author","Kowallick, Johannes T."],["dc.contributor.author","von Haehling, Stephan"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Schuster, Andreas"],["dc.date.accessioned","2022-10-04T10:21:43Z"],["dc.date.available","2022-10-04T10:21:43Z"],["dc.date.issued","2022"],["dc.description.abstract","Background\r\n The risk of myocarditis after mRNA vaccination against COVID-19 has emerged recently. Current evidence suggests that young male patients are predominantly affected. In the majority of the cases, only mild symptoms were observed. However, little is known about cardiac magnetic resonance (CMR) imaging patterns in mRNA-related myocarditis and their differences when compared to classical viral myocarditis in the acute phase of inflammation.\r\n \r\n \r\n Methods and results\r\n \r\n In total, 10 mRNA vaccination-associated patients with myocarditis were retrospectively enrolled in this study and compared to 10 patients suffering from viral myocarditis, who were matched for age, sex, comorbidities, and laboratory markers. All patients (\r\n n\r\n = 20) were hospitalized and underwent a standardized clinical examination, as well as an echocardiography and a CMR. Both, clinical and imaging findings and, in particular, functional and volumetric CMR assessments, as well as detailed tissue characterization using late gadolinium enhancement and T1 + T2-weighted sequences, were compared between both groups. The median age of the overall cohort was 26 years (group 1: 25.5; group 2: 27.5;\r\n p\r\n = 0.57). All patients described chest pain as the leading reason for their initial presentation. CMR volumetric and functional parameters did not differ significantly between both groups. In all cases, the lateral left ventricular wall showed late gadolinium enhancement without significant differences in terms of the localization or in-depth tissue characterization (late gadolinium enhancement [LGE] enlargement: group 1: 5.4%; group 2: 6.5%;\r\n p\r\n = 0.14; T2 global/maximum value: group 1: 38.9/52 ms; group 2: 37.8/54.5 ms;\r\n p\r\n = 0.79 and\r\n p\r\n = 0.80).\r\n \r\n \r\n \r\n Conclusion\r\n This study yielded the first evidence that COVID-19 mRNA vaccine-associated myocarditis does not show specific CMR patterns during the very acute stage in the most affected patient group of young male patients. The observed imaging markers were closely related to regular viral myocarditis in our cohort. Additionally, we could not find any markers implying adverse outcomes in this relatively little number of patients; however, this has to be confirmed by future studies that will include larger sample sizes."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2022"],["dc.identifier.doi","10.3389/fcvm.2022.965512"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/114481"],["dc.notes.intern","DOI-Import GROB-600"],["dc.relation.eissn","2297-055X"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0/"],["dc.title","Cardiovascular magnetic resonance imaging patterns of acute COVID-19 mRNA vaccine-associated myocarditis in young male patients: A first single-center experience"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","45"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Cardiovascular Magnetic Resonance"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Lange, Torben"],["dc.contributor.author","Backhaus, Sören J."],["dc.contributor.author","Beuthner, Bo E."],["dc.contributor.author","Topci, Rodi"],["dc.contributor.author","Rigorth, Karl-Rudolf"],["dc.contributor.author","Kowallick, Johannes T."],["dc.contributor.author","Evertz, Ruben"],["dc.contributor.author","Schnelle, Moritz"],["dc.contributor.author","Ravassa, Susana"],["dc.contributor.author","Díez, Javier"],["dc.contributor.author","Toischer, Karl"],["dc.contributor.author","Seidler, Tim"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Schuster, Andreas"],["dc.date.accessioned","2022-08-18T12:40:06Z"],["dc.date.available","2022-08-18T12:40:06Z"],["dc.date.issued","2022-07-28"],["dc.date.updated","2022-07-29T12:18:01Z"],["dc.description.abstract","Abstract\n \n Background\n Since cardiovascular magnetic resonance (CMR) imaging allows comprehensive quantification of both myocardial function and structure we aimed to assess myocardial remodeling processes in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR).\n \n \n Methods\n CMR imaging was performed in 40 patients with severe AS before and 1 year after TAVR. Image analyses comprised assessments of myocardial volumes, CMR-feature-tracking based atrial and ventricular strain, myocardial T1 mapping, extracellular volume fraction-based calculation of left ventricular (LV) cellular and matrix volumes, as well as ischemic and non-ischemic late gadolinium enhancement analyses. Moreover, biomarkers including NT-proBNP as well as functional and clinical status were documented.\n \n \n Results\n Myocardial function improved 1 year after TAVR: LV ejection fraction (57.9 ± 16.9% to 65.4 ± 14.5%, p = 0.002); LV global longitudinal (− 21.4 ± 8.0% to -25.0 ± 6.4%, p < 0.001) and circumferential strain (− 36.9 ± 14.3% to − 42.6 ± 11.8%, p = 0.001); left atrial reservoir (13.3 ± 6.3% to 17.8 ± 6.7%, p = 0.001), conduit (5.5 ± 3.2% to 8.4 ± 4.6%, p = 0.001) and boosterpump strain (8.2 ± 4.6% to 9.9 ± 4.2%, p = 0.027). This was paralleled by regression of total myocardial volume (90.3 ± 21.0 ml/m2 to 73.5 ± 17.0 ml/m2, p < 0.001) including cellular (55.2 ± 13.2 ml/m2 to 45.3 ± 11.1 ml/m2, p < 0.001) and matrix volumes (20.7 ± 6.1 ml/m2 to 18.8 ± 5.3 ml/m2, p = 0.036). These changes were paralleled by recovery from heart failure (decrease of NYHA class: p < 0.001; declining NT-proBNP levels: 2456 ± 3002 ng/L to 988 ± 1222 ng/L, p = 0.001).\n \n \n Conclusion\n CMR imaging enables comprehensive detection of myocardial remodeling in patients undergoing TAVR. Regression of LV matrix volume as a surrogate for reversible diffuse myocardial fibrosis is accompanied by increase of myocardial function and recovery from heart failure. Further data are required to define the value of these parameters as therapeutic targets for optimized management of TAVR patients.\n Trial registration DRKS, DRKS00024479. Registered 10 December 2021—Retrospectively registered, \n https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00024479"],["dc.identifier.citation","Journal of Cardiovascular Magnetic Resonance. 2022 Jul 28;24(1):45"],["dc.identifier.doi","10.1186/s12968-022-00874-0"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112977"],["dc.language.iso","en"],["dc.publisher","BioMed Central"],["dc.rights.holder","The Author(s)"],["dc.subject","Cardiac magnetic resonance imaging"],["dc.subject","Transcatheter aortic valve replacement"],["dc.subject","Myocardial remodeling"],["dc.subject","Assessment of myocardial function and structure"],["dc.title","Functional and structural reverse myocardial remodeling following transcatheter aortic valve replacement: a prospective cardiovascular magnetic resonance study"],["dc.type","journal_article"],["dspace.entity.type","Publication"]]